Insilico Medicine to Begin Phase I USP1 Inhibitor Trial Following FDA IND Clearance
The firm's IND application was supported by preclinical studies showing activity of ISM3091 against BRCA-mutant and homologous repair-deficient cancers.
FDA Expert Panel Recommends Lynparza, Zytiga Combo Only for BRCA1/2-Mutated Prostate Cancer Patients
The ODAC made the recommendation based on data from the PROpel trial, which demonstrated the greatest benefit in patients with BRCA1/2-mutated mCRPC.
An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.
NICE Reverses Course, Recommends Lynparza for BRCA1/2-Mutated Breast, Prostate Cancer
NICE previously said Merck and AstraZeneca's PARP inhibitor wasn't cost-effective but has reconsidered after striking a discounted commercial deal with the drugmakers.
Tailored Phone Calls Increased Rate of Genetic Testing, Counseling for Hereditary Cancer Risk
A Rutgers Cancer Institute study showed that phone education is more effective at spurring patients to get genetic cancer risk assessment than mailed brochures.